Elucid News

Latest Elucid news, funding rounds and robotics & AI coverage. $55M raised. 1 article tracked by The Robotics Media.

About Elucid

Elucid is a Boston-based cardiovascular medical imaging company applying artificial intelligence to standard coronary CT angiography (CCTA). Its Plaque-IQ software is the only FDA-cleared, non-invasive imaging platform that quantifies high-risk plaque tissue types across coronary and carotid arteries, validated against ex-vivo histopathology. Elucid is also preparing to launch BioIntegrated FFR-CT to measure lesion-level physiology without invasive catheterisation.

Key facts

• Headquarters: Boston, Massachusetts, United States
• Country: United States
• Founded: 2011
• Sectors: AI Foundation Models, Medical Imaging
• Website: https://elucid.com

Products by Elucid

• Plaque-IQ (Software, 2024) — FDA-cleared, AI-driven CT angiography software that classifies and quantifies coronary and carotid plaque, including lipid-rich necrotic cores, in interactive 3...
• BioIntegrated FFR-CT (Software, 2026) — Non-invasive fractional flow reserve calculation that combines fluid dynamics with plaque morphology, under FDA 510(k) review as of 2026.

Funding rounds

• Series D — $55M — 2026 — led by IAG Capital Partners

Latest Elucid news

• Elucid Raises $55M Series D To Push AI Heart-Scan Platform Into US Cardiology — Boston’s Elucid closes an oversubscribed $55 million Series D to expand its FDA-cleared Plaque-IQ software and prepare its BioIntegrated FFR-CT tool f...